Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / termination-notice.docx
termination-notice.docx
Parties
HARKNESS LLP
Cole LLP
Penterra Pharmaceuticals Corp
Dates
September 30, 2024
June 10, 2024
December 10, 2024
August 14, 2024
August 22, 2024
August 28, 2024
September 6, 2024
September 13, 2024
April 3, 2024
Amounts
$900,000,000
$87.3
$45,000,000
Obligations
Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Agreement
1(c) of the Agreement, the "Outside Date" by which the Closing must occur is December 10, 2024, being six (6) months from the date of the Agreement
2(a) of the Agreement conditions Buyer's obligation to consummate the Closing upon the representations and warranties of the Company and the Sellers set forth in Article III of the Agreement being true and correct in all respects (or, with respect to representations and warranties not qualified by materiality or Material Adverse Effect, true and correct in all material respects) as of the date of the Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation or warranty expressly relates to an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date)
The Company is required to submit a complete response to the FDA addressing the clinical hold issues before the FDA will consider lifting the clinical hold
The significance of these events must be understood in the context of the Company's business and financial profile
75 mg/kg means that the Company must generate new clinical data demonstrating the safety and efficacy of VRD-4187 at the reduced dose level